Trial
NCT05613894
Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase ISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Utah
Collaborators
Exelixis
Condition
Metastatic Castration-resistant Prostate Cancer
Intervention
Cabozantinib
Why stopped
DSMC Safety Analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-29